8-Methyl-3-(2-phenylethynyl)-8-azabicyclo[3.2.1]oct-2-ene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-Methyl-3-(2-phenylethynyl)-8-azabicyclo[3.2.1]oct-2-ene
• 化学式: C₁₆H₁₇N
• 分子量: 223.31
• InChiKey: PWGAVFOAURZTIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Novel azacyclic ethynyl derivatives
  申请人：Peters Dan

  公开号：US20050171078A1

  公开（公告）日：2005-08-04

  This invention relates to novel azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型的氮杂环乙炔衍生物，发现它们是烟碱乙酰胆碱受体的胆碱能配体，同时也是单胺受体和转运体的调节剂。由于它们的药理特性，本发明中的化合物可能有助于治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或疾病，与平滑肌收缩相关的疾病或疾病，内分泌疾病或疾病，神经退行性疾病或疾病，与炎症，疼痛和化学物质滥用终止引起的戒断症状相关的疾病或疾病。
• NOVEL AZACYCLIC ETHYNYL DERIVATIVES
  申请人：NEUROSEARCH A/S

  公开号：EP1506205A2

  公开（公告）日：2005-02-16
• US7378526B2
  申请人：——

  公开号：US7378526B2

  公开（公告）日：2008-05-27
• US7667040B2
  申请人：——

  公开号：US7667040B2

  公开（公告）日：2010-02-23
• [EN] NOVEL AZACYCLIC ETHYNYL DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'ETHYNYL AZACYCLIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2003094830A2

  公开（公告）日：2003-11-20

  This invention relates to novel azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.